Skip to content

Standard (D1) versus extended (D2) lymph node dissection during gastrectomy for gastric cancer in Italy: a randomised comparison of morbidity, mortality and survival

Italian Gastric Cancer Study Group (IGCSG) randomised clinical trial of morbidity, mortality and survival after D1 and D2 gastrectomy for gastric cancer in western patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN11154654
Enrollment
320
Registered
2009-04-07
Start date
1998-06-01
Completion date
Unknown
Last updated
2021-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer Cancer Malignant neoplasm of stomach

Interventions

The study was performed according to the rules of the JRGC as regards the extent of stomach removal and the technique of lymph-node dissection (D1 and D2 procedures) and to the Japanese Classification

Sponsors

Health Research Aimed at the Regione Piemonte (Ricerca Sanitaria Finalizzata della Regione Piemonte) (Italy)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Histology proven and potentially curable gastric adenocarcinoma, not requiring emergency surgery 2. Aged younger than 80 years, either sex 3. In adequate physical condition without serious co-morbid cardio-respiratory diseases which could preclude a safe D2 procedure 4. Have not undergone previous gastric surgery 5. Does not harbor a coexisting cancer

Exclusion criteria

Exclusion criteria: 1. Absence of macroscopic involvement of liver and peritoneum (HO, PO) 2. Absence of macroscopic involvement of adjacent organs (T less than 4) 3. Absence of macroscopic massive involvement of N2 nodes (enlarged nodes at coeliac area) 4. Absence of malignant cells in para-aortic nodes (16B1) at biopsy and frozen section 5. Absence of malignant cells in peritoneal washing fluid, during intra-operative fresh examination 6. Absence of macroscopic residual tumour (RO) 7. No involvement of the oesophagus, cardia or duodenum

Design outcomes

Primary

MeasureTime frame
Survival: follow-up for mortality analysed with the Kaplan-Mayer risk assessment.

Secondary

MeasureTime frame
1. Complications (general and surgical) and reoperations assessed post-operatively 2. Hospital mortality, defined as death occurring within 30 days from the procedure or during patient's hospital stay Follow-up was done at regular intervals (4 months) and follow-up data were sent every 6 months to the Reference Centre where all data were collected.

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 31, 2026